The neurodegenerative disorder spinocerebellar ataxia type 7 (SCA7) is caused by a polyglutamine (polyQ) expansion in the ataxin-7 protein, categorizing SCA7 as one member of a large class of heritable neurodegenerative proteinopathies. Cleavage of ataxin-7 by the protease caspase-7 has been demonstrated in vitro, and the accumulation of proteolytic cleavage products in SCA7 patients and mouse models has been identified as an early pathological change.
INTRODUCTION
4 huntingtin (Htt) protein can be cleaved in vitro by extracts taken from apoptotic cells (10) . It was subsequently shown that only N-terminal epitopes of Htt are detectable in protein aggregates (11) (12) (13) (14) , and neo-epitopes resulting from cleavage events can be detected in presymptomatic and mildly affected HD patients (15) . Fragments in HD can also form by non-proteolytic processes, such as aberrant splicing (16) . The role of protein context in mediating the toxicity of polyQ disease proteins is particularly well established in HD. YAC128 mice that express full-length human Htt with 128 glutamine residues show HD-like signs, as do HD transgenic "fragment" models that express only Htt exon 1 (17) . Furthermore, YAC128 mice that express a caspase-6 resistant version of human Htt do not develop neurodegeneration and motor deficits, while equivalent mice lacking this point mutation do (18) .
In our first transgenic mouse model of SCA7, we detected an N-terminal proteolytic truncation fragment of ataxin-7 that migrated at a molecular mass of ~ 55 kDa (19) . To fully characterize ataxin-7 proteolysis, we tested the ability of various caspases to cleave ataxin-7, and we found that recombinant caspase-7 cleaves ataxin-7 in vitro (20) . Site-directed mutagenesis of two putative caspase-7 cleavage sites (D266N and D344N) eliminated caspase-7 proteolysis, diminished polyQ-ataxin-7 toxicity and aggregation, and ameliorated polyQ-ataxin-7 transcriptional interference in cell culture. These studies suggested that cleavage at the aspartic acid residue at amino acid position 266 is primarily responsible for the reduction of toxicity. In this study, we examined the role of ataxin-7 proteolytic cleavage in SCA7 disease pathogenesis in transgenic mice, and found that an intact proteolytic cleavage site at amino acid position 266 is required for polyQ-ataxin-7 neurotoxicity.
RESULTS

Production and Characterization of Transgenic Mouse Lines
In our earlier work, we created a SCA7 transgenic mouse model by placing an ataxin-7-92Q cDNA under the control of the murine prion protein (MoPrP) promoter, as this transgenic vector typically drives neuronal and retinal expression at levels similar to endogenous murine SCA7 (21, 22) . To determine if caspase cleavage of ataxin-7 contributes to SCA7 neurotoxicity in vivo, we began with a similar MoPrP-ataxin-7 construct and mutated the aspartic acid residue at amino acid position 266 to an asparagine (D266N), as prior work demonstrated that caspase-7 can cleave ataxin-7 protein at this amino acid residue, and expression of ataxin-7-92Q-D266N yields reduced toxicity in a SCA7 neuron cell culture model (20) . Prior to microinjection, we confirmed that both PrP-ataxin-7 cDNA transgenic constructs produce full-length ataxin-7
protein by Western blot analysis of transiently transfected mouse neuroblastoma (Neuro2A) cells (Fig. 1B) . After we identified transgene-positive PrP-ataxin-7-92Q and PrP-ataxin-7-92Q-D266N founders, we crossed the founders onto a C57BL/6J strain background and measured the expression of human transgenic ataxin-7 relative to murine endogenous ataxin-7 by competitive RT-PCR (22) . We chose this RNA-based quantification method because ataxin-7 protein is known to form insoluble aggregates that are difficult to quantify by Western blot analysis. In this way, we obtained five lines of transgenic mice, and established four lines of transgenic mice (i.e. two lines from each genotype) with similar ataxin-7-92Q expression levels ( Fig. 2A , Table 6 D266N line 1239 (hereafter referred to as the "D266N" line), we focused primarily upon these two lines during the course of this study (Table 1) .
The D266N Mutation Prevents Cleavage of Ataxin-7 and Attenuates Retinal Dysfunction
To determine if the D266N mutation affects caspase-7 cleavage of ataxin-7 ex vivo, we incubated cerebellar lysates from SCA7 and D266N lines with recombinant caspase-7. SCA7 lysate without the addition of caspase-7 exhibited very little fragment, while the addition of caspase-7 caused the appearance of an ~55 kDa fragment that was immunoreactive with an antibody raised against the N-terminus of ataxin-7 (Fig. 2C ). This cleavage fragment is readily apparent in line 283 (Fig. 2C) , a high-expressing SCA7 transgenic line that we could not maintain due to the severity of the phenotype (Table1). Lysate from D266N mice lacked this cleavage fragment after recombinant caspase-7 treatment (Fig. 2C) , indicating that the D266N mutation prevents caspase-7 cleavage of ataxin-7. As reported previously (20) , we also observed a minor 65 kDa cleavage product in the presence of the D266N mutation (Fig. 2C , noted by *).
To assess the effect of the D266N mutation on retinal function, we evaluated retinal histopathology and performed electroretinogram (ERG) analysis. Retinal tissue from 24 weekold SCA7 mice exhibited a loss of cone photoreceptor cells and outer nuclear layer thinning, while D266N and WT retinas appeared normal (Fig. 3A-C) . Quantification of retinal photoreceptor number revealed a significant reduction in SCA7 mice relative to the D266N line and WT controls (Fig. 3D) . Upon ERG analysis, SCA7 mice at 22 weeks of age exhibited a significantly impaired rod photoreceptor depolarization response, while the response of D266N rod photoreceptors was not statistically different from non-transgenic littermates (Fig. 4) . This indicates that the D266N mutation substantially attenuates retinal dysfunction, indicating that cleavage of ataxin-7 is a required step for manifestation of the full SCA7 retinal phenotype.
The D266N Mutation Ameliorates the Neurobehavioral Phenotype in SCA7 Mice
We used multiple behavioral measures to compare the phenotypes of SCA7, D266N and littermate WT mice. In humans, SCA7 causes a progressive loss of coordination due to cerebellar degeneration. We used an accelerating rotarod apparatus to assess the coordination function of these three cohorts of mice. At 8 weeks of age, there was no difference between SCA7, D266N, and WT mice in latency to fall off the rotarod (Fig. 5A) . At 14 weeks, however, the SCA7 mice had a shorter latency to fall than either WT or D266N mice (Fig. 5A ). To further explore the behavioral phenotype, we used multiple measures of physical coordination and neurological function. We determined the degree of clasping and kyphosis in each line. D266N mice were not different from WT mice in either clasping or kyphosis, while SCA7 mice were significantly impaired in both measures (Fig. 5B) . We then assessed the physical coordination of each line using the ledge test. By this measure, WT and D266N mice were not statistically different at 8 or 14 weeks, while SCA7 mice exhibited a robust and statistically significant impairment (Fig. 5B) . Finally, as an additional measure, we evaluated the extent of kyphosis as an indication of neuromuscular dysfunction and found that SCA7 transgenic mice scored significantly higher compared to D266N and WT mice (Fig. 5B) . Together, this indicates that the D266N mutation confers a substantial degree of protection from SCA7 neurological dysfunction in transgenic mice.
To determine the extent of cerebellar neuropathology in the SCA7 transgenic mice, we performed immunohistochemistry on SCA7, D266N, and WT mice at 24 weeks of age. We observed a modest decrease in Purkinje cell neuron dendritic arborization in the cerebellar molecular layer in SCA7 mice, while Purkinje cell dendritic arborization appeared normal in the D266N mice ( Fig. 6A-C) . We also measured glutamate uptake in cerebellar synaptosome preparations from SCA7, D266N, and WT mice, and observed a significant decrease in GLASTmediated glutamate uptake in SCA7 transgenic mice relative to WT and D266N mice (Fig. 6D ).
D266N transgenic mice displayed glutamate uptake that was not significantly different from WT controls (Fig. 6D ).
The D266N Mutation Significantly Prolongs Survival of SCA7 Transgenic Mice
To determine the mean lifespan of SCA7 and D266N mice, we aged mice from matched generations and compared their age of euthanasia due to severe morbidity. SCA7 mice lived an average of 17.1 weeks, while D266N mice survived 57.3 weeks on average (Fig. 7 , Table 1 ).
This greater than 3-fold extension of survival time in D266N mice indicates a substantial protection from SCA7 pathology. To statistically analyze the life span extension observed in the D266N mice, we compared the life spans of the SCA7, D266N, and WT cohorts using a KaplanMeyer plot (Fig. 7) . Statistical analysis of the Kaplan-Meyer plot revealed a highly significant increase in lifespan for the D266N line (p < 0.0001), as >90% of the D266N mice outlived all of their SCA7 counterparts. SCA7 transgenic mice with a second site D344N mutation blocking this proteolytic site were also created and characterized as part of this study, but were not protected from SCA7 behavioral abnormalities, neuropathology, or decreased survival, despite comparable transgene-expression levels (data not shown).
DISCUSSION
Proteolytic cleavage is a common theme in neurodegenerative disease, ranging from inherited polyQ disorders to idiopathic disorders such as Alzheimer's disease (23) . Here we found that mutating the caspase-7 cleavage site of ataxin-7 at an aspartic acid residue at amino acid position 266 significantly attenuates the SCA7 disease phenotype in transgenic mice. D266N mice displayed an extended life span, a mild behavioral phenotype, and only modest abnormalities of retinal histopathology and visual function when compared to SCA7 mice expressing ataxin-7-92Q protein without the D266N mutation. Indeed, even when the ataxin-7-92Q D266N transgene was expressed in a second independent line of mice (Line 2357) at levels that were ~70% greater than ataxin-7-92Q, these D266N transgenic mice still lived twice as long as their SCA7 counterparts and exhibited reduced retinal disease and neurological dysfunction (Table 1 ).
This suggests that proteolytic cleavage of ataxin-7 is a crucial event in the SCA7 disease process, and provides further support for the "toxic fragment hypothesis" which posits that proteolytic processing of polyQ disease proteins is required for full toxicity (24, 25) .
In the case of SCA7, caspase-7 has been implicated as the likely protease responsible for cleaving the ataxin-7 protein (20) . Caspase-7 is an executioner caspase whose activation typically occurs downstream of so-called initiator caspases (26) ; however, non-apoptotic activation of executioner caspases has been observed under conditions of CNS stress (27) .
While mutation of the aspartic acid residue at position 266 of ataxin-7-92Q protein substantially ameliorated the SCA7 disease phenotype, the D266N mice did ultimately develop progressive SCA7 disease that led to their demise. The slow progression of SCA7 polyQ neurotoxicity upon mutation of the putative caspase-7 cleavage site suggests that full-length polyQ-expanded ataxin-aggregates are not the cause of polyQ disease; rather, insoluble conformers that form oligomers are likely the primary pathogenic agent.
How does the truncated ataxin-7-92Q protein fragment produce neurotoxicity? Akin to a number of other polyQ disease proteins with normal functions in transcription, ataxin-7 is known to shuttle into and out of the nucleus, as it possesses functional nuclear localizations signals and a functional nuclear export signal (NES) at amino acid position 341 -352 (31). When we tested the effect of mutation of the NES domain upon ataxin-7 toxicity in primary cerebellar granule neurons, we noted increased toxicity of NES mutant, full-length polyQ-expanded ataxin-7 that was accompanied by markedly increased nuclear aggregation (31) , suggesting that impaired nuclear export of polyQ-expanded ataxin-7 promoted nuclear accumulation of ataxin-7 and cellular toxicity. As activated caspase-7 interacts with ataxin-7 in the nucleus (20) , our findings are consistent with a model in which proteolytic cleavage of full-length polyQ-expanded ataxin-7 in the nucleus prevents its egress from the nucleus, promoting its retention and accumulation, thereby driving neurotoxicity. Of particular relevance to this model of nuclear toxicity, ataxin-7 is a component of the STAGA transcription co-activator complex, and studies have shown that polyQ-expanded ataxin-7 can impair the GCN5-dependent histone acetyltransferase activity of the STAGA complex (32, 33) . Furthermore, ataxin-7 also serves as an adapter protein between the STAGA transcriptional co-activator complex and the USP22 histone deubiqutinase module, and may serve as a scaffold linking these two chromatin-remodeling activities (34, 35) . Both STAGA acetyltransferase activity and USP22 deubiquitination activity are important for the regulation of specific genes, including retinal genes (32, 34) . In yeast, loss-of-function of Sgf73, the ataxin-7 orthologue, disrupts the interaction between the yeast STAGA complex (SAGA) and the yeast USP22 module (Ubp8). This yields a marked reduction in Ubp8-mediated histone H2B deubiquitination, increasing the level of ubiquitinated H2B (36, 37) . As H2B ubiquitination regulates gene silencing at specific loci in the yeast genome (37) , this likely is a functionally deleterious alteration. As the aspartic acid residue at position 266 in human (and mouse) ataxin-7 is located between two highly conserved regions known respectively as "conserved block I" and "conserved block II", cleavage at this position may sever the interaction and cross-talk between histone deubiquination and acetylation and thus exert a profound toxic effect upon STAGA complex function. Thus, accumulation of truncated polyQ-ataxin-7 could alter regulation of the USP22 deubiquitination activity or Gcn5 acetyltransferase activity within neurons and glia.
Our results indicate that inhibition of polyQ-ataxin-7 proteolytic cleavage could be a highly effective therapeutic intervention. The D266N transgenic line survived approximately 3 times longer than the SCA7 line, exhibited a substantially attenuated behavioral phenotype, and displayed minimal retinal histopathology and visual dysfunction. If caspase-7-mediated proteolytic cleavage is a critical element of SCA7 disease pathogenesis, then inhibition of caspase-7 cleavage of ataxin-7 may hold promise as a treatment for human SCA7 patients.
Therapeutic strategies would include pharmacological options (38) , if a specific caspase-7 inhibitor capable of crossing the blood-brain barrier could be identified, or genetic interventions, as targeted delivery of viral vectors expressing a caspase-7 specific RNA interference sequence or of caspase-7 antisense oligonucleotides might be plausible. Since the proteolytic cleavage event occurs early in the pathogenic cascade, our findings in SCA7, together with studies of HD and AD (23) , suggest that therapeutic protease inhibition is worthy of consideration for a broad range of neurodegenerative disorders.
MATERIAL AND METHODS
Transgenic Constructs
Constructs were created from human SCA7 cDNA vectors using site-directed PCR mutagenesis as described previously (20) . In contrast to the previous generation of SCA7 transgenic mice, the current constructs carry N-terminal FLAG and C-terminal c-myc epitope tags.
Production of Transgenic Mice
All animal work was approved by the IACUC at the University of Washington, Buck Institute, and UCSD. Constructs were verified for correct electrophoretic migration and expression level by transient transfection into the murine neuroblastoma N2a cell line using Lipofectamine 2000 (Invitrogen). NotI digestion followed by agarose gel separation was used to isolate the expression cassette from the vector backbone. The SCA7 cassette was then microinjected into the pronuclei of oocytes from C57BL/6J -C3H/HeJ F1 hybrid mice. Founders were identified using the following primers designed to selectively amplify the SCA7 cDNA: SCA7-440 F, CCGAGA ATGGATGGCACACT; SCA7-440 R, TGCGGTGGTTGCTGAGAGT. The following primers were designed to amplify a fragment of mouse genomic DNA, and were included in genotyping reactions as an internal control: mPrp-957 F, AAAGGGCTGTTCTCAGAGGCAC; mPrp-957 R, CTGCATGACCTGAAGCAAAATCA.
Transgenic mice were backcrossed with C57BL/6J mice for at least ten generations.
Expression Analysis of Transgenic Mice
Expression was determined by competitive PCR. RNA was extracted from cerebellar tissue and reverse transcribed using random hexamer primers. A portion of the cDNA was amplified in the presence of 33 P-labeled dCTP (1.5 Ci per 20 L reaction) using primers that anneal equally to human and murine ataxin-7 to produce an amplicon of 1322 bp from both the murine gene and human transgene. The primer sequences are 5'-GGAAAAACCGCGAAGTCATGGGGCTCTG-3' and 5'-CCATAGCTGTGCAT-TCAGATGCTTCTC-3'. The resulting amplicons were digested using Xmn I, which cleaves the murine and human amplicons differently, and then resolved by polyacrylamide gel electrophoresis. The gel was dehydrated and analyzed by phosphorimager (Molecular Dynamics).
Behavioral Analysis of Transgenic Mice
All behavioral experiments were performed in a blinded manner. To measure coordination, mice were challenged on an Economex Accelerating Rotarod apparatus and the latency to fall was recorded. Speed was set to 4 rpm and increased at a rate of 0.1 rpm per second, to a maximum time of 5 minutes. Latency to fall was recorded. This procedure was repeated five times per day for four consecutive days. Statistical significance was determined for each day by one-way ANOVA. Three additional measures were used to assess SCA7-like neurodegenerative signs:
the degree of clasping, the ledge test, and the degree of kyphosis. The ledge test has been described previously (19) . Clasping, kyphosis, and the ledge test were recorded on a scale of 0-3, with larger numbers indicating a more pronounced phenotype (39) . These measures were performed once per day for five consecutive days, and results from each week were averaged.
Statistical differences between groups were examined using one-way ANOVA and Turkey's multiple comparison test.
Western Blot Analysis
Mouse cerebella or retinas were homogenized in sample buffer (62.5 mM Tris-HCl pH 6.8, 4%
SDS, 200 mM dithiothreitol, 10% glycerol, 0.001% Bromophenol blue) and heated for 10 min at Retinal sections were blocked in 2% horse serum, 1% BSA, and 0.1% Triton X-100 in PBS.
Cerebellar and retinal sections were probed with primary antibodies in 0.3% Triton X-100 in PBS. Primary antibodies used for IHC in this study were rabbit -red cone opsin 1:200 (Chemicon, #AB5405); rabbit -ataxin-7 1:300 (Affinity BioReagents, #PA1-749); mouse -calbindin D-28K 1:500 (Swant, #300); and rabbit -GFAP 1:400 (Dako Cytomation, #Z0334).
Primary antibody staining was visualized with fluorophore-conjugated secondary antibodies.
For cerebellar IHC, we generated coronal sections from the midpoint of the cerebellum at a thickness of 40 m for all mice, and compared sets of sections from 3 mice / genotype.
Electroretinograms
Mice were anesthetized using isoflurane gas. A gold wire contact electrode was placed on the corneas, and a reference electrode was inserted subdermally on the dorsal side of the neck. Rod responses were recorded in response to white light flashes from -20 to +20 dB at 10 dB intervals.
Glutamate uptake
Cerebellar synaptosome preparations and glutamate uptake assays were performed as previously described (42).
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was performed, as previously described (La Spada et al., 2001 ). All samples were run in triplicate and the average of the three runs was rounded to the nearest 0.01. We were unable to maintain the high-expressing B283 line beyond the N2 generation. 
ND = not determined
ABBREVIATIONS
CNS central nervous system
Spt3-Taf9-Gcn5 acetyltransferase (STAGA)
by guest on November 7, 2016 
